- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01957254
Investigate the Activity of Endotoxin in Severe Sepsis
Investigate the Activity of Endotoxin in Patients With Severe Sepsis and Septic Shock
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
Endotoxin is the major mediator of gram-negative bacteria which cause the systemic inflammation and result in microcirculatory dysfunction, and it leads to multiple organ dysfunction and death in patients with severe sepsis and septic shock.
The goal of this study is to measure the endotoxin activity of patients with severe sepsis and septic shock at certain time points, and furthermore, to compare the difference of endotoxin activity among different pathogens, infection source, and antibiotics. The study will enroll severe sepsis and septic shock patients.
The endotoxin activity will be measured by Limulus Amebocyte Lysate (LAL) test. Limulus Amebocyte Lysate (LAL) test will be used to detect and quantify serum level of endotoxin. The critical component of the LAL reagents used in endotoxin tests is derived from blood cells (amebocytes) of the horseshoe crab, Limulus polyphemus. It contains the proteins of the blood clotting mechanism, which is triggered by endotoxins. LAL reagents are primarily used to test for endotoxins in injectable pharmaceuticals, biological products, and medical devices. They are also used in renal dialysis centers and a wide range of other applications. LAL tests are described in the Bacterial Endotoxins Test chapter in the United States Pharmacopeia (Chapter 85) and in the equivalent chapters in the European Pharmacopoeia (Chapter 2.6.14) and the Japanese Pharmacopoeia (Part I, General Tests, No. 6). We will adopt the chromogenic method as purchased from the Associates of Cape Cod Inc. (ACC). The LAL reagent is formulated with a synthetic substrate which gives a yellow color when acted upon by endotoxin activated enzyme. The test is read at 405 nm, usually in a microplate reader. The severity of multiple organ dysfunction and 28-day mortality will be followed up.
Tipo di studio
Iscrizione (Effettivo)
Contatti e Sedi
Luoghi di studio
-
-
-
Taipei, Taiwan
- National Taiwan University Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
- ICU patients with new onset of severe sepsis and septic shock
- Presence of at least 2 of the following conditions (These criteria should have occurred between 12 hours before or 6 hours after the onset of the qualifying first organ dysfunction)
- Fever or hypothermia (body temperature over 38 ℃ or under 36 ℃
- Tachycardia (heart rate > 90 bpm)
- Tachypnea (respiratory rate over 20 breaths/min or under mechanical ventilation)
- Leukocyte count more than 12,000 cells/mm3, less than 4,000 cells/mm3, or more than 10 % of immature form (band)
Exclusion Criteria:
Patient will be excluded if they
- are under 20 years old or older than 99 years old
- have suffered from severe sepsis or septic shock more than 24 hours
- are pregnant
- were treated with another medicine or device in the trial less than 30 days prior to the admission to this trial
- have received organ transplantation less than 1 years prior to this trial
- are terminally ill, for examples with metastasis, with a life expectancy of less than 30 days (certified by the attending physician)
- have already received other blood cleaning treatments, such as CVVH, HD, HF, and PE upon entry into the trial
- have chosen palliative care and signed Do Not Resuscitate sheet
- non-native speaker
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Coorti e interventi
Gruppo / Coorte |
---|
Severe Sepsis
Patient with severe sepsis
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Endotoxin activity
Lasso di tempo: baseline
|
The endotoxin activity will be measured by Limulus Amebocyte Lysate (LAL) test.
Limulus Amebocyte Lysate (LAL) test will be used to detect and quantify serum level of endotoxin.
|
baseline
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Change of endotoxin activity
Lasso di tempo: At enrollment, 24h, 48h, and 72h
|
Compare the change of endotoxin activity at different time points.
|
At enrollment, 24h, 48h, and 72h
|
Collaboratori e investigatori
Investigatori
- Investigatore principale: Yu-Chang Yeh, Ph.D., Department of Anesthesiology, National Taiwan University Hospital
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Anticipato)
Completamento dello studio (Anticipato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 201211040RIB
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Shock settico
-
Assistance Publique - Hôpitaux de ParisTraumabase Group; Capgemini Invent; Ecole polytechnique; EHESS (Ecole des hautes... e altri collaboratoriReclutamentoFerite e lesioni | Shock emorragico | Shock traumaticoFrancia
-
King's College Hospital NHS TrustUniversity Hospital BirminghamCompletatoShock emorragico traumaticoRegno Unito
-
Haukeland University HospitalMinistry of Defence, NorwayCompletatoShock emorragico | Shock ipovolemicoNorvegia
-
Massachusetts General HospitalBeth Israel Deaconess Medical Center; Boston Medical Center; Tufts Medical Center; Lahey Clinic e altri collaboratoriReclutamento
-
Jason SperryNational Heart, Lung, and Blood Institute (NHLBI)TerminatoShock emorragicoStati Uniti
-
University of Texas Southwestern Medical CenterUniversity of Washington; Resuscitation Outcomes ConsortiumCompletato
-
Arsenal Medical, Inc.Non ancora reclutamentoTrauma | Shock emorragico | Emorragia dissanguante | Shock; TraumaticoStati Uniti
-
Ramathibodi HospitalSconosciutoShock settico | Shock refrattarioTailandia
-
German Center for Neurodegenerative Diseases (DZNE)University Hospital, BonnSconosciutoSepsi grave con shock settico | Sepsi grave senza shock setticoGermania
-
Assiut UniversitySconosciuto